McKesson reported third-quarter fiscal 2026 adjusted earnings of $9.34 per share, surpassing the Zacks Consensus Estimate of $9.31 and representing a 16% increase over the $8.03 per share achieved in the same period last year. While the company did not disclose an exact revenue figure in its earnings release, consensus expectations had been for approximately $105.5 billion, reflecting a projected 10.8% year-over-year rise in pharmaceutical and medical-supply distribution volumes driven by both generic and specialty drug segments.

The company has increased its full-year adjusted EPS guidance range by $0.20 at the midpoint, now forecasting between $36.50 and $37.00 per share for fiscal 2026. This upgrade rests on strong performance in oncology and high-margin specialty drug distribution, where volume growth exceeded 12% in Q3. Management cited new contract wins with three major biopharma partners and expanded capacity in cold-chain logistics as key drivers of the profit uplift.

Analysts point to a price-to-earnings ratio of 26.03, indicating that the stock trades at a premium to peers based on trailing earnings. The current ratio stands at 0.88, below the 1.0 threshold, suggesting tighter short-term liquidity. McKesson’s debt-to-equity ratio is a negative 5.63, reflecting substantial lease liabilities and finance-lease obligations exceeding shareholder equity. Investors will monitor free cash flow conversion, which management says remains strong, with operating cash flow expected to cover capital expenditures by more than 1.3x for the full year.